Zydus Cadila’s US arm -- Nesher Pharmaceuticals has received the final approval from the US Food and Drug Administration (USFDA) to market Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and Amphetamine Sulfate, Extended Release Capsules, 5 mg, 10 mg, 15 mg, 20 mg and 25 mg.
The drug is indicated for the treatment of Attention-Deficit Hyperactivity Disorder which is a brain disorder characterized by an ongoing pattern of inattention and, or hyperactivity-impulsivity that interferes with functioning or development. It will be manufactured at Nesher Pharmaceuticals’ manufacturing facility located at St. Louis, MO, USA.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
